Trial Profile

Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary)
Indications COVID 2019 infections; Hypoxaemia; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use

Most Recent Events

17 May 2021 Results of assessing troponin or natriuretic peptide levels among hospitalized patients with COVID-19 presented at the 70th Annual Scientific Session of the American College of Cardiology
02 Feb 2021 Results published in the Annals of Internal Medicine
14 Dec 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com